A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera…
Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and…
Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI…
James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe. In…
In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain…
François Bayrou’s new administration in France, sworn in after the previous, three-month-old government was toppled by a no-confidence vote, brings a new health minister to a post recently characterized by…
A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma;…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the…
With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies,…
See our Cookie Privacy Policy Here
